Arcturus Therapeutics Holdings Inc.ARCT
What Arcturus Therapeutics Holdings Inc. does.
We are a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics. We have ongoing Phase 2 clinical studies for our RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF).
We developed the world’s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE ® (“KOSTAIVE”), which we have partnered with Seqirus, Inc. (“CSL Seqirus”), a part of CSL Limited. KOSTAIVE has achieved approval in Japan, the European Union and the United Kingdom as a vaccine against COVID-19, and sales of KOSTAIVE began in Japan in October 2024.
We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based therapeutics for rare genetic disorders with significant unmet medical needs and vaccines for infectious diseases. Current mRNA medicines have two critical components: the messenger RNA (“mRNA”) constructs and the lipid nanoparticles (“LNP”) which help deliver the mRNA to disease-relevant target tissues. We have extensive expertise in the design and optimization of mRNA constructs, including with respect to a type of mRNA technology known as self-amplifying mRNA (sa-mRNA). Our proprietary self-amplifying mRNA technology platform, or STARR ® (“STARR”), has been demonstrated to induce a robust, longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines. Our proprietary LNP delivery system, LUNAR ® (“LUNAR”), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues. LUNAR may enable multiple nucleic acid medicines. We also have significant expertise and valuable know-how in the development and scalability of complex and robust manufacturing processes required to deliver the next generation of nucleic acid medicines.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.5M | $12.4M | $206.0M | $166.8M | $152.3M | $82.0M |
| Net income | -$72.1M | -$203.7M | $9.3M | -$29.7M | -$80.9M | -$65.8M |
| Free cash flow | -$44.6M | -$138.4M | $24.3M | -$21.0M | -$60.4M | -$74.5M |
More on ARCT.
- Arcturus Therapeutics Holdings Inc. summary
- Arcturus Therapeutics Holdings Inc. financial statements
- Arcturus Therapeutics Holdings Inc. key metrics
- Arcturus Therapeutics Holdings Inc. health scores and style box
- Arcturus Therapeutics Holdings Inc. earnings
- Arcturus Therapeutics Holdings Inc. dividends
- Arcturus Therapeutics Holdings Inc. valuation
- Arcturus Therapeutics Holdings Inc. ownership and insiders
- Arcturus Therapeutics Holdings Inc. peers
Figures from Arcturus Therapeutics Holdings Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.